The TRUST-II study (NCT04919811) is a global multicenter Phase 2 study to assess the efficacy and safety of taletrectinib in people with advanced or metastatic ROS1-positive NSCLC and other cancers.

The study started in September 2021 and is actively recruiting participants.  

The study has enrolled participants in nine countries in Asia, Europe and North America and continues to actively recruit participants in Japan, France, Italy, Spain, Canada and the United States. 

Depending on their cancer type and previous treatment, participants will be enrolled into this study and be divided into different groups (cohorts).

More about TRUST-II study 

Key eligibility criteria for TRUST-II

Key Inclusion Criteria

  • Age ≥18 years (or ≥20 years as required by local regulations).
  • Histologically or cytologically confirmed diagnosis of locally advanced or metastatic NSCLC or other solid tumors.
  • Evidence of ROS1 fusion in tumor tissue determined by a validated assay as performed in CLIA-certified or locally equivalent diagnostic laboratories. 
  • Patients with CNS involvement, including leptomeningeal carcinomatosis, which is either asymptomatic or previously treated and controlled, are allowed.
  • The patient is either ROS1 TKI treatment naïve, or treated with prior ROS1 TKI(s)
  • ECOG Performance Status: 0 or 1.
  • Patients with adequate organ function (Bone Marrow, Hepatic, Renal)

Exclusion Criteria

  • Treatment with other investigational agents or anticancer therapy within 2 weeks  
  • Previously treated with immune therapy including immune checkpoint inhibitors within 4 weeks before enrollment.
  • Major surgery within 4 weeks prior to enrollment.
  • Radiation therapy with a limited field for palliation within 1 week before study treatment
  • AEs due to prior therapy are unresolved to ≤ CTCAE Grade 1 except for AEs not constituting a safety risk to the patient in the judgment of investigators.
  • Active and clinically significant bacterial, fungal, or viral infection including HBV, HCV, or SARS-CoV-2, known HIV and AIDS-related illness.

Study site list in the US

Please refer to the study sites indicated in the map.



RecruitingBeverly Hills Cancer Center
Beverly Hills, California, 90211

RecruitingMoores Cancer Center at UC San Diego
La Jolla, California, 92037

RecruitingKeck Medicine of University of Southern California
Los Angeles, California, 90089

RecruitingUCI Medical Center
Orange, California, 92868

RecruitingPMK Medical Group Inc
Oxnard, California, 93030

RecruitingAmerican Institute of Research
Whittier, California, 90601


RecruitingSCRI - Florida Cancer Specialists South
Fort Myers, Florida, 33901

RecruitingMemorial Healthcare System
Hollywood, Florida, 33021

RecruitingCancer Specialists of North Florida
Jacksonville, Florida, 92868


RecruitingSCRI - Hematology Oncology Clinic
Baton Rouge, Louisiana, 70809


RecruitingMayo Clinic
Rochester, Minnesota, 55902

New Jersey

Active, not recruitingCenter for Cancer Research
Brick, New Jersey, 08724


RecruitingCleveland Clinic Foundation
Cleveland, Ohio, 44195


RecruitingSCRI - Tennessee Oncology
Nashville, Tennessee, 37203


RecruitingRenovatio Clinical
Dallas, Texas, 75001

RecruitingTexas Oncology, P.A.
Dallas, Texas, 75246

RecruitingRenovatio Clinical - The Woodlands
Houston, Texas, 77056


RecruitingNorthwest Medical Specialties PLLC
Tacoma Washington, 98405

ROS1 Positive Non- Small Cell Lung Cancer

Lung cancer is a type of cancer that begins in the cells of lung. Lung cancer is the leading cause of cancer death worldwide.

There are two types of lung cancer: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). About 80% to 85% of lung cancers are NSCLC.

Most lung cancers do not cause any symptoms until they have spread, but some people with early lung cancer do have symptoms.

more about ROS1

What is taletrectinib?

Taletrectinib is an investigational targeted therapy known as a ROS1 tyrosine kinase inhibitor (TKI). It is a pill that is taken orally. Targeted therapy is a type of cancer treatment that targets proteins that control how cancer cells grow, divide, and spread.

Taletrectinib is a next-generation potent, selective, brain penetrant, ROS1 TKI designed to overcome some of the challenges with existing ROS1 therapies. The results from both non-clinical and clinical studies showed that taletrectinib could stop the function of certain proteins that may help cancer grow. It has shown clinical activity in people who have had prior ROS1 TKI treatment and in those who have not. It has also shown clinical activity in people with ROS1 positive NSCLC who have brain metastasis.

More about Taletrectinib



For more information about the TRUST-II study contact